Lazela (Ranolazine)

Lazela (ranolazine) is used in the management of ischemic heart disease, specifically chronic angina syndromes.

• Chronic stable angina: reduces the frequency of angina attacks and improves exercise capacity.
• Angina pectoris: alleviates chest‑pain episodes during physical exertion.
• Refractory angina: provides symptom relief when conventional anti‑anginal therapies are insufficient.

• Ranolazine selectively inhibits the late inward sodium current (INaL) in cardiac myocytes. By lowering intracellular sodium, it indirectly reduces calcium overload via the Na⁺/Ca²⁺ exchanger, decreasing myocardial wall tension and oxygen consumption. This improves cardiac efficiency without markedly affecting heart rate or blood pressure.

Ranolazine may cause a range of adverse reactions, which are categorized by frequency and severity.

Common Side Effects

• Dizziness
• Nausea
• Constipation
• Headache
• Fatigue
• Palpitations

Serious or Rare Side Effects

• Prolonged QT interval
• Severe arrhythmias
• Hepatotoxicity
• Hypotension (rare)
• Syncope
• Stevens‑Johnson syndrome

When prescribing Lazela, clinicians should consider several safety measures and patient‑specific factors.

• Assess cardiac history: evaluate for existing QT prolongation or arrhythmias.
• Review concomitant medications: avoid drugs that also prolong QT interval.
• Monitor liver function: periodic tests recommended during long‑term therapy.
• Adjust dose in renal impairment: consider reduced dosing in severe renal dysfunction.
• Counsel patients on symptoms: advise to report palpitations, fainting, or severe dizziness promptly.
• Store at ambient temperature: keep below 25 °C in the original container, protected from moisture and light.

Ranolazine interacts with several medicines, requiring attention to avoid adverse outcomes.

Major Interactions (Avoid)

• Strong CYP3A4 inhibitors (e.g., ketoconazole, clarithromycin): may markedly increase ranolazine plasma levels.
• Strong CYP2D6 inhibitors (e.g., quinidine, paroxetine): can raise ranolazine concentrations and risk toxicity.
• Other QT‑prolonging agents (e.g., sotalol, amiodarone): combined use may exacerbate cardiac repolarization delay.

Moderate Interactions (Monitor Closely)

• Moderate CYP3A4 inducers (e.g., rifampin, carbamazepine): may reduce efficacy.
• Digoxin: ranolazine can increase digoxin levels; monitor serum concentrations.
• Anticoagulants (e.g., warfarin): may require INR monitoring due to potential interaction.